123 related articles for article (PubMed ID: 35927049)
1. [Multiple pulmonary nodules with interstitial changes].
Yang SQ; Hao M; Gao YL; Zhang YH; Yang MF; Jin ML; Fang Q
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):783-789. PubMed ID: 35927049
[TBL] [Abstract][Full Text] [Related]
2. 68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report.
Tanriverdi O; Tarimer ML; Pak CD; Uylas S; Alkan A; Celik OI; Kilic RM; Zeybek A
J Oncol Pharm Pract; 2021 Jun; 27(4):984-989. PubMed ID: 32830600
[TBL] [Abstract][Full Text] [Related]
3. [Diffuse pulmonary meningotheliomatosis: a case report and literature review].
Ding YL; Zhu H; Yang W; Liu BB; Zhu X; Li MJ; He B
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Jan; 42(1):24-29. PubMed ID: 30630245
[No Abstract] [Full Text] [Related]
4. Evaluating the Patient With a Pulmonary Nodule: A Review.
Mazzone PJ; Lam L
JAMA; 2022 Jan; 327(3):264-273. PubMed ID: 35040882
[TBL] [Abstract][Full Text] [Related]
5. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
6. [Multivariate Analysis of Solid Pulmonary Nodules Smaller than 1 cm in
Distinguishing Lung Cancer from Intrapulmonary Lymph Nodes].
Tang J; Liu C; Wang P; Cui Y
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):94-98. PubMed ID: 33508896
[TBL] [Abstract][Full Text] [Related]
7. Multiple primary lung cancer versus intrapulmonary metastatic cancer: A case of multiple pulmonary nodules.
Liu C; Li H; Xu K; Song S; He Y; Cai X; Chu X; Yang J; Cui Y
Thorac Cancer; 2019 Feb; 10(2):352-358. PubMed ID: 30548923
[TBL] [Abstract][Full Text] [Related]
8. Occult mediastinal lymph node metastasis in FDG-PET/CT node-negative lung adenocarcinoma patients: Risk factors and histopathological study.
Miao H; Shaolei L; Nan L; Yumei L; Shanyuan Z; Fangliang L; Yue Y
Thorac Cancer; 2019 Jun; 10(6):1453-1460. PubMed ID: 31127706
[TBL] [Abstract][Full Text] [Related]
9. [HRCT features differentiate synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases].
Zhou LN; Wu N; Zhao SJ; Yang L; Wang YL; Wang RB; Yang SX
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):449-455. PubMed ID: 32575939
[No Abstract] [Full Text] [Related]
10. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
11. Ground-glass nodule in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-positive lung cancer: a case report.
Owada Y; Yonechi A; Higuchi M; Suzuki H
World J Surg Oncol; 2016 Mar; 14():81. PubMed ID: 26964537
[TBL] [Abstract][Full Text] [Related]
12. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
13. Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma.
Wang H; Zhang W; Wang K; Li X
Medicine (Baltimore); 2018 Jun; 97(26):e11116. PubMed ID: 29952952
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of lung adenocarcinoma after an interval of 15 years revealed by demonstration of the same type of EML4-ALK fusion gene.
Tsukamoto Y; Kanamori K; Watanabe T; Mikami K; Ieki R; Nakano T; Kajimoto K; Hirota S
Pathol Res Pract; 2014 Dec; 210(12):1112-6. PubMed ID: 25238939
[TBL] [Abstract][Full Text] [Related]
15. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
16. Effect of CT window settings on size measurements of the solid component in subsolid nodules: evaluation of prediction efficacy of the degree of pathological malignancy in lung adenocarcinoma.
Li Q; Gu YF; Fan L; Li QC; Xiao Y; Liu SY
Br J Radiol; 2018 Jul; 91(1088):20180251. PubMed ID: 29791206
[TBL] [Abstract][Full Text] [Related]
17. Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next-generation sequencing.
Qiu T; Li W; Zhang F; Wang B; Ying J
Cancer Biol Ther; 2020; 21(2):170-177. PubMed ID: 31651223
[No Abstract] [Full Text] [Related]
18. [Alectinib for an Octogenarian Patient with Poor Performance Status and ALK Fusion Gene-Positive Lung Cancer-A Case Report].
Kamiyoshihara M; Igai H; Matsuura N; Yazawa T; Ohsawa F
Gan To Kagaku Ryoho; 2021 Aug; 48(8):1053-1055. PubMed ID: 34404075
[TBL] [Abstract][Full Text] [Related]
19. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
Kaira K; Naruse I; Shimizu K; Asao T
J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary nodule detection in oncological patients - Value of respiratory-triggered, periodically rotated overlapping parallel T2-weighted imaging evaluated with PET/CT-MR.
de Galiza Barbosa F; Geismar JH; Delso G; Messerli M; Huellner M; Stolzmann P; Veit-Haibach P
Eur J Radiol; 2018 Jan; 98():165-170. PubMed ID: 29279157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
